Table 3 Benefits and drug costs over 1-year for a practice population of 10,000 resulting from the introduction of these treatments assuming the total benefit of the drugs
From: Implementing guidelines in primary care: can population impact measures help?
Number Needed to Treat (NNT) | Disease Impact Number (DIN) | Population Impact Number (PIN) | Number to be Treated in your Population (NTP) | Number of Events Prevented in your Population (NEPP) | Total drug cost (€) | Drug cost per death prevented (€) | ||
|---|---|---|---|---|---|---|---|---|
MI | ACE-I | |||||||
ACE-I | 69 | 93 | 1,653 | 147 | 2.12 | 14,700 | 6,944 | |
BB | 48 | 64 | 1,150 | 147 | 3.04 | 6,615 | 2,174 | |
Statin | 53 | 66 | 1,181 | 157 | 2.96 | 60,525 | 20,423 | |
Aspirin | 93 | 103 | 1,837 | 176 | 1.91 | 1,940 | 1,019 | |
MI + CHF | ||||||||
ACE-I | 23 | 31 | 5,109 | 16 | 0.69 | 1,575 | 2,299 | |
BB | 16 | 22 | 3,649 | 16 | 0.96 | 709 | 739 | |
Spironolactone | 11 | 15 | 2,554 | 16 | 1.37 | 2,268 | 1,655 |